Late-Onset Cold Agglutinin Syndrome Following Nivolumab Therapy: A Delayed Immune-Related Adverse Event with Masked Hemolysis – A Case Report
Case Reports in Oncology · 2026-08-22 · 19 (1) · 1485-1492
DOI: 10.1159/cro/abzag012 ↗Abstract
Introduction: Cold agglutinin syndrome (CAS) is a secondary form of cold antibody-mediated autoimmune hemolytic anemia. Immune checkpoint inhibitor-associated CAS is exceedingly uncommon and poses particular diagnostic challenges in critically ill patients. Case Presentation: A 66-year-old male with metastatic squamous cell lung carcinoma was admitted to the intensive care unit (ICU) for respiratory failure, with a course complicated by sepsis and continuous renal replacement therapy (CRRT). On ICU day 24, hemoglobin-hematocrit (Hb-Hct) discordance was identified; peripheral blood smear confirmed erythrocyte agglutination. Direct antiglobulin testing (DAT) revealed C3d positivity with negative IgG, and the cold agglutinin titer was 1/64. Total and indirect bilirubin were elevated. Quantitative immunoglobulin concentrations did not demonstrate an elevated IgM level; however, serum protein electrophoresis, immunofixation, and bone marrow examination could not be completed, so an occult clonal B-cell disorder could not be definitively excluded. The clinical presentation was considered more consistent with probable secondary CAS than with primary cold agglutinin disease (CAD). CAS was diagnosed as a delayed immune-related adverse event (irAE) approximately 14 months after nivolumab discontinuation. No recognized infectious trigger classically associated with cold agglutinin-mediated hemolysis was identified. A malignancy-associated mechanism could not be completely excluded but was considered less likely. Causality was assessed using the Naranjo Adverse Drug Reaction Probability Scale (score: 6; probable adverse drug reaction). Rituximab was withheld due to refractory sepsis and hemodynamic instability. Management consisted of active thermal control (CRRT circuit temperature maintained at 38°C), warmed erythrocyte transfusions, and avoidance of cold exposure. Conclusion: This case highlights that CAS may emerge as a delayed irAE following nivolumab therapy. Hb-Hct discordance should be recognized as an early diagnostic clue when classical hemolytic markers are masked. Active thermal control during CRRT represents a practical strategy to limit hemolysis.
EUVIMED